SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
HONG KONG, Nov 4, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, Mr. Shanchun WANG has been appointed as the President (China) of the Company. Mr. Wang will mainly be responsible for the China operation.Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company. Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization. He is a specialist that granted the special government allowances of the State Council and awarded as a national model worker, a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Tec...
